<div><div><h2>Sun Pharma posts Q2 loss at  219 crore on one-time charge</h2></div><div> industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement. india s largest drugmaker by market capitalisation made a provision of  1214 crore ($167 million) for estimated settlements with remaining plaintiffs in us antitrust litigation related to its sleep disorder drug modafinil leaving it with a  219 crore loss in the three months to september . 30 the company said on tuesday. adjusted net for the quarter was  996 crore against a  912 crore profit in the same period last year and analyst expectations for a profit of  1035 crore according to i/b/e/s data from refinitiv. total from operations was  6938 crore up 4.3% while us sales which account for more than a third of total sales rose 11% to $342 million. indian pharmaceutical companies have been hit by us regulatory bans and warnings over quality control violations at production plants which have weighed on profitability. pricing pressure has also weighed on performance in the united states though sales have begun to show improvement.</div></div>